Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline

Journal of the Canadian Urological Association

Volumn 4, Issue 4, 2010, Pages 263-267

  Miles, Brendan J W ^a   Fairey, Adrian S ^b   Eliasziw, Michael ^c   Estey, Eric P ^b   Venner, Peter ^b   Finch, Daygen ^b   Trpkov, Kiril ^c   Eigl, Bernhard J ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957724898     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj09134     Document Type: Article

References (13)

1. National Comprehensive Cancer Care Network. NCCN clinical practice guidelines in oncology: bladder cancer including upper tract tumours and urothelial carcinoma of the prostate. http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf. Accessed July 9, 2010.
2. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-1934.
3. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004;171:561-569.
4. David KA, Milowsky MI, Ritchey J, et al. Low incidence of Perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer data base. J Urol 2007;178:451-454.
5. Alberta Cancer Board Provincial GU Tumour Team: Clinical practice guideline GU002 bladder cancer, 7/07 update. http://www.cancerboard.ab.ca/NR/rdonlyres/F57CDB83-009F-4AC7-96A8-085C7642F56A/0/GU_002_Bladdercancer.pdf. Accessed July 9, 2010.
6. Fairey A, Chetner M, Metcalfe J, et al. Associations among age, comorbidity and clinical outcomes after radical cystectomy: results from the Alberta Urology Institute radical cystectomy database. J Urol 2008;180:128-134.
7. Sobin LH, Wittekind CH, editors. UICC TNM classification of malignant tumours. 6th ed. New York, NY: Wiley-Liss; 2002.
8. Dash A, Pettus IV JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. Cancer 2008;113:2471-2477.
9. Grossman BH, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
10. Splinter J, Scher HI, Denis L, et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J Urol 1992;147:606-608.
11. Bassi P, Ferrante GD, Piazza N, et al: Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999;161:1494-1497.
12. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.
13. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-4608.